Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Business Wire December 20, 2022

Merck Leaders Recognized As Influential Women Executives

Accesswire December 16, 2022

AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer

Business Wire December 15, 2022

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Accesswire December 13, 2022

Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

Business Wire December 12, 2022

In Burkina Faso, a Personal Mission To Make a Difference in One Community

Accesswire December 2, 2022

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting

Business Wire December 1, 2022

Merck Announces First-Quarter 2023 Dividend

Business Wire November 29, 2022

Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Business Wire November 22, 2022

SHAREHOLDER ALERT: Weiss Law Investigates Imago BioSciences, Inc.

PR Newswire November 21, 2022

Merck to Acquire Imago BioSciences, Inc.

Business Wire November 21, 2022

Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference

Business Wire November 21, 2022

LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer

Business Wire November 14, 2022

Our Partnerships Help Make Vaccines Accessible Worldwide

Accesswire November 9, 2022

Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies

Business Wire November 7, 2022

Dedicated To Developing Women Leaders

Accesswire November 2, 2022

Veeva and Merck Form Long-Term Strategic Partnership

PR Newswire November 1, 2022

Merck Announces Third-Quarter 2022 Financial Results

Business Wire October 27, 2022

Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck

Business Wire October 26, 2022

European Commission Expands Merck's VAXNEUVANCE(TM) (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents

Business Wire October 24, 2022